MENLO PARK, Calif.-- Intersect ENT, Inc. (XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2016.

 

Third quarter 2016 revenue was $18.5 million, representing a 30% increase over the third quarter 2015.

Third quarter 2016 gross margin was 85% compared to 80% in the third quarter 2015.

Key recent highlights include:

 

Reporting of positive topline results of the RESOLVE II clinical study. The study met both primary efficacy endpoints: reduction in nasal congestion and polyp burden. RESOLVE II, a 300-patient randomized, blinded, multi-center clinical trial, evaluated the placement of the investigational RESOLVE steroid releasing implant in the physician’s office.

MASON, Ohio-- AtriCure, Inc. (ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2016 financial results.

 

“We are pleased to report solid third quarter results led by sales in the U.S. and driven by all areas of our business,” said Mike Carrel, President and Chief Executive Officer of AtriCure. “Our focus on improving patient outcomes continues to guide our clinical and commercial efforts, and we are well-positioned to reach EBITDA profitability in 2018 and for sustainable success.”

 

Third Quarter 2016 Financial Results

Revenue for the third quarter of 2016 was $38.3 million, an increase of $6.9 million or 22.0% (22.0% on a constant currency basis), compared to third quarter 2015 revenue. U.S. revenue increased 24.0% to $30.6 million, driven by strong sales of ablation-related open-heart products, ablation-related minimally invasive products, and AtriClip® products. International revenue was $7.8 million, an increase of $1.0 million or 14.9% (14.7% on a constant currency basis). International revenue growth was driven primarily by increases in product sales in Japan, Italy, Russia and France.

SYLMAR, Calif.--- Second Sight Medical Products, Inc. (EYES) (Second Sight or the Company), a developer, manufacturer and marketer of implantable visual prosthetics to restore functional vision to blind patients, today announced the first successful implantation and activation of a wireless visual cortical stimulator in a human subject, providing the initial human proof of concept for the ongoing development of the Company’s Orion™ I Visual Cortical Prosthesis (Orion I). In the UCLA study supported by Second Sight, a 30 year old patient was implanted with a wireless multichannel neurostimulation system on the visual cortex and was able to perceive and localize individual phosphenes or spots of light with no significant adverse side effects.

 

Dr. Robert Greenberg, Chairman of the Board of Second Sight, said, “It is rare that technological development offers such stirring possibilities. This first human test confirms that we are on the right track with our Orion I program to treat blind patients who cannot benefit from the Argus® II Retinal Prosthesis (Argus II). 

WAYNE, PA--(Oct 5, 2016) - ICTV Brands, Inc. (ICTV), ( CSE : ITV ), a digitally focused, direct response marketing and branding company specializing in the health, wellness and beauty sector, today announced the signing of a definitive agreement to acquire the consumer products business of PhotoMedex, Inc. ( NASDAQ :PHMD ) for a total consideration of $9.5 million.

 

The agreement calls for ICTV to acquire the assets of PhotoMedex's flagship product no!no!, along with the Kyrobak and Cleartouch brands. The purchase price of $9.5 million consists of a $3 million cash payment on closing, $2 million cash payment due on the 90th day following the closing, and a $4.5 million capped royalty based on future net sales of the acquired product lines. This asset purchase will include the respective product trademarks, patents, and other intellectual property, along with manufacturing tooling, and PhotoMedex's Hong Kong and Brazilian subsidiaries. ICTV will also receive a minimum of $6 million of GAAP inventory.